Validating the primary care posttraumatic stress disorder screen for DSM-5 (PC-PTSD-5) in a substance misusing, trauma-exposed, socioeconomically vulnerable population.
Validating the primary care posttraumatic stress disorder screen for DSM-5 (PC-PTSD-5) in a substance misusing, trauma-exposed, socioeconomically vulnerable population.
复制标题
在滥用药物、遭受创伤、社会经济弱势群体中验证 DSM-5 (PC-PTSD-5) 初级保健创伤后应激障碍筛查。
DOI：
10.1016/j.addbeh.2022.107592
复制
发表时间：
2023
影响因子：
4.4
通讯作者：
Powers,Abigail
中科院分区：
文献类型：
--
作者：
Patton,SamanthaC;Hinojosa,CeciliaA;Lathan,EmmaC;Welsh,JustineW;Powers,Abigail
物质使用障碍（SUD）和创伤后应激障碍（PTSD）的共同发生是常见的，并且与更严重的症状、更差的治疗预后以及治疗后再次使用物质的风险增加有关。尽管有临床意义，但PTSD筛查并没有在药物使用治疗项目中常规实施。确定筛查工具，使患者负担最小化，并允许在这一患者群体中进行综合治疗是至关重要的。目前的研究检验了初级保健PTSD筛查forDSM-5（PC-PTSD-5）在鉴别81名社会经济条件不利的药物滥用医院患者中可能的PTSD的效用。大多数样本（75.3%,n= 61）被发现符合PTSD诊断标准，使用PTSD检查表forDSM-5（PCL-5）中建议的临床cut score为33分。完成诊断效用分析并确定PC-PTSD-5的cut-score为5，表现出最佳表现(SE = 0.62, κ(1) = 0.22；Sp = 0.80, κ(0) = 0.61；EEF = 0.67, κ(0.5) = 0.32)。结果初步支持使用PC-PTSD-5作为药物滥用患者群体中可能的PTSD的简短筛查工具。在评估过程中常规使用PC-PTSD-5可能有利于制定治疗计划，因为全面的评估和治疗将提供更好的长期康复机会。
The co-occurrence of substance use disorder (SUD) and posttraumatic stress disorder (PTSD) is common, and is associated with greater severity of symptoms, poorer treatment prognosis, and increased risk of return to substance use following treatment. Screening for PTSD is not routinely implemented in substance use treatment programs, despite clinical relevance. Identifying screening tools that minimize patient burden and allow for comprehensive treatment in this patient population is critical. The current study examined the utility of the Primary Care PTSD Screen forDSM-5(PC-PTSD-5) in identifying probable PTSD in a predominantly Black sample of 81 socioeconomically disadvantaged substance misusing hospital patients. The majority of the sample (75.3 %;n= 61) were found to meet criteria for probable PTSD using a suggested clinical cut score of 33 on the PTSD Checklist forDSM-5(PCL-5). Diagnostic utility analyses were completed and determined a cut-score of 5 for the PC-PTSD-5 to demonstrate the best performance (SE = 0.62, κ(1) = 0.22; SP =.80, κ(0) = 0.61; EEF = 0.67, κ(0.5) = 0.32) in this sample. Results provide preliminary support for the use of the PC-PTSD-5 as a brief screening tool for probable PTSD in substance misusing patient populations. Routine use of the PC-PTSD-5 during assessment may be beneficial when treatment planning with those undergoing treatment for SUD because comprehensive assessment and treatment will provide a better chance of long-term recovery.